X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Cardinal Health will provide cGMP product manufacturing of ready-to-use TCT for Clarity’s U.S.-based clinical trials from its Center for Theranostics Advancement. TCT are radiopharmaceuticals that pair copper-64 (64Cu) and copper-67 (67Cu) for diagnosis and therapy.
Lead Product(s): 67Cu-labelled MeCOSar-Tyr3-octreotate
Therapeutic Area: Oncology Product Name: 67Cu-SARTATE
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Recipient: Clarity Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 02, 2021
Details:
Cardinal Health will provide comprehensive end-to-end 3PL to Sesen Bio in support of commercialization in the U.S. The Company’s lead program, Vicineum is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive NMIBC.
Lead Product(s): Vicineum
Therapeutic Area: Oncology Product Name: VB4-845
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sesen Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
